Evolution of endocrine adjuvant therapy for early breast cancer

Expert Opinion on Investigational Drugs

Volumn 19, Issue SUPPL. 1, 2010, Pages

  Lønning, Per Eystein ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Adjuvant therapy; Breast cancer; Endocrine therapy; Oestrogen; Oestrogen receptor

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DROLOXIFENE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; EXEMESTANE; FLUOROURACIL; GESTAGEN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GOSERELIN; GROWTH FACTOR; KI 67 ANTIGEN; LETROZOLE; METHOTREXATE; NORTAMOXIFEN; PROGESTERONE RECEPTOR; PROTEIN INHIBITOR; RANK LIGAND INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER RESISTANCE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MENOPAUSAL SYNDROME; MONOTHERAPY; OVARIECTOMY; OVERALL SURVIVAL; PHARMACOGENETICS; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK FACTOR; SIGNAL TRANSDUCTION; SURGICAL TECHNIQUE; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 77950647817     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543781003714865     Document Type: Conference Paper

References (106)

1. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481
2. Abe O, Abe R, Enomoto K, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717
3. Lønning PE. Additive endocrine therapy for advanced breast cancer-back to the future. Acta Oncol 2009;48:1092-1101
4. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399-1411
5. Mouridsen H, Gershanovick M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol 2003;21:2101-2109
6. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981;304:16-21
7. Lundgren S. Progestins in breast cancer treatment. Acta Oncol 1992;31:709-722
8. Lønning PE, Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 1988;35:685-710
9. McGuire WL. Steroid receptors in human breast cancer. Cancer Res 1978;38:4289-4291
10. Degenshein GA, Bloom N, Tobin E. The value of progesterone receptor assays in the management of advanced breast cancer. Cancer 1980;46:2789-2793 (Pubitemid 11205632)
11. McGuire WL, Horwitz KB, Pearson OH, et al. Current status of estrogen and progesterone receptors in breast cancer. Cancer 1977;39:2934-2947
12. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-168
13. Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-1979
14. Horwitz KB, McGuire WL. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975;189:726-727
15. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005;23:7512-7517
16. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816
17. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008;26:1059-1065
18. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007;25:3846-3852
19. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Nat Acad Sci 2001;98:10869-10874
20. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423
21. Lønning PE, Sørlie T, Børresen-Dale A-L. Genomics in breast cancer-therapeutic implications? Nat Clin Pract Oncol 2005;2:26-33
22. Lippman M, Bolan G, Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976;36:4595-4601
23. Masamura S, Santner SJ, Heitjan DF, et al. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-2925
24. Dowsett M, Martin LA, Smith I, et al. Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol 2005;95:167-172
25. Lønning PE, Taylor PD, Anker G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine treatment. Breast Cancer Res Treat 2001;67:111-116
26. Flageng MH, Moi LLH, Dixon JM, et al. Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br J Cancer 2009;101:1253-1260
27. Jordan VC. The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer-survival or death? J Clin Oncol 2008;26:3073-3082
28. Osborne CK, Schiff R. Aromatase inhibitors: future directions. J Steroid Biochem Mol Biol 2005;95:183-187
29. Yue W, Fan P, Wang JP, et al. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 2007;106:102-110
30. Carlomagno C, Perrone F, Gallo C, et al. C-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14:2702-2708
31. Johnston S, Pegram M, Press M, et al. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR plus) metastatic breast cancer (MBC): first results from the EGF30008 trial. Cancer Res 2009;69:74S-5S
32. Rasmussen BB, Regan MM, Lykkesfeldt AE, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008;9:23-28
33. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99:167-170
34. Ellis MJ, Tao Y, Luo JQ, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100:1380-1388
35. Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results From Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008;26:5569-5575
36. Kuiper GG, Enmark E, Pelto-Huikko, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-5930
37. Mosselman S, Polman J, Dijkema R. ER beta identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49-53
38. Speirs V. The evolving role of oestrogen receptor beta in clinical breast cancer. Breast Cancer Res 2008;10(5):111
39. Zhang WH, Andersson S, Cheng GJ, et al. Update on estrogen signaling. FEBS Lett 2003;546:17-24
40. Honma N, Horii R, Iwase T, et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008;26:3727-3734
41. Shaaban AM, Green AR, Karthik S, et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008;14:5228-5235
42. Lønning PE, Lien E. Mechanisms of action of endocrine treatment in breast cancer. Crit Rev Oncol Haematol 1995;21:158-193
43. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-1764
44. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25:5187-5193
45. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-121
46. Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008;99:995-999
47. Lash TL, Lien EA, Sorensen HT, et al. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 2009;10:825-833
48. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009;9:576-586
49. Ma CX, Adjei AA, Salavaggione OE, et al. Human aromatase: gene resequencing and functional genomics. Cancer Res 2005;65:11071-11082
50. Colomer R, Monzo M, Tusquets I, et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008;14:811-816
51. Clarke M, Collins R, Davies C, et al. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996;348:1189-1196
52. Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormone- releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711-1723
53. Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002;20:4628-4635
54. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002;20:4621-4627
55. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-690
56. Stewart HJ, Prescott RJ, Forrest APM. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001;93:456-462
57. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996;88:1828-1833
58. Peto R, Davies C. ATLAS (adjuvant tamoxifen, longer against shorter): International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women-preliminary results. Breast Cancer Res Treat 2008;109:586
59. Klijn JGM, Beex LVAM, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000;92:903-911
60. Klijn JGM, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-353
61. Caleffi M, Fentiman IS, Clark GM, et al. Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain. J Endocrinol 1988;119:335-339
62. Groom GV, Griffiths K. Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 1976;70:421-428
63. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-2139
64. Lønning PE, Jacobs S, Jones A, et al. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer 1991;63:789-793
65. Fex G, Adielsson G, Mattson W. Oestrogen-like effects of tamoxifen on the concentration of proteins in plasma. Acta Endocrinol 1981;97:109-113
66. Lønning PE, Hall K, Aakvaag A, et al. Influence of tamoxifen on the plasma levels of insulin-like growth factor I and Insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 1992;52:4719-4723
67. Buzdar A, Hayes D, El-Khoudary A, et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 2002;73:161-175
68. Bruning PF. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer. 1992;28A:1404-1407
69. Lønning PE, Johannessen DC, Lien EA, et al. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 1995;52:491-496
70. Geisler J, Haarstad H, Gundersen S, et al. Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. J Endocrinol 1995;146:359-363
71. Helle SI, Anker G, Tally M, et al. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. J Steroid Biochem Mol Biol 1996;57:167-171
72. Geisler J, Ekse D, Hosch S, et al. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 1995;55:193-195
73. Decensi A, Robertson C, Viale G, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-790
74. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-691
75. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-4882
76. Lønning PE. Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)? J Clin Oncol 2008;26:4859-4861
77. Kohno N. Treatment of breast cancer with bone metastasis: bisphosphonate treatment-current and future. Int J Clin Oncol 2008;13:18-23
78. Yuasa T, Kimura S, Ashihara E, et al. Zoledronic acid-a multiplicity of anti-cancer action. Curr Med Chem 2007;14:2126-2135
79. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440:692-696
80. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006;24:5769-5779
81. Parulekar WR, Day AG, Ottaway JA, et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCICCTG MA.5. J Clin Oncol 2005;23:6002-6008
82. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006;24:1045-1051
83. Lønning PE. Adjuvant endocrine treatment of early breast cancer. Hematol Oncol Clin North Am 2007;21:223-238
84. Lønning PE, Geisler J. Indications and limitations of third-generation aromatase inhibitors. Expert Opin Invest Drugs 2008;17:723-739
85. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (intergroup exemestane study): a randomised controlled trial. Lancet 2007;369:559-570
86. Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormonesensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006;7:991-996
87. Pocock SJ. The simplest statistical test: how to check for a difference between treatments. BMJ 2006;332:1256-1258
88. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757
89. Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53
90. Mouridsen HT, Giobbie-Hurder A, Mauriac L, et al. BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Cancer Res 2009;69:66S-7S
91. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766-776
92. Rea D, Hasenburg A, Seynaeve C, et al. Five years of exemestane as initial therapy compared to 2-3 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer [abstract 11]. Cancer Res 2009;69:487s
93. Lønning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 2006;17:217-225
94. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:1948-1955
95. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684
96. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672
97. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999;26:78-83 (Pubitemid 29411436)
98. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648
99. Slamon DJ, LeylandJones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792
100. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752
101. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005;97:1254-1261
102. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between, HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-153 (Pubitemid 36193263)
103. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
104. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712
105. Kaufman B, Mackey J, Clemens M, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized Phase III TAnDEM study. J Clin Oncol 2009;27:5529-5537
106. Lønning PE. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer 2009;45:527-535